PL3402821T3 - Przeciwciało wiążące psma i jego zastosowania - Google Patents

Przeciwciało wiążące psma i jego zastosowania

Info

Publication number
PL3402821T3
PL3402821T3 PL17701290.3T PL17701290T PL3402821T3 PL 3402821 T3 PL3402821 T3 PL 3402821T3 PL 17701290 T PL17701290 T PL 17701290T PL 3402821 T3 PL3402821 T3 PL 3402821T3
Authority
PL
Poland
Prior art keywords
psma
applications
binding antibody
antibody
binding
Prior art date
Application number
PL17701290.3T
Other languages
English (en)
Inventor
Helmut Salih
Fabian Vogt
Gundram Jung
Latifa ZEKRI-METREF
Original Assignee
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
Eberhard Karls Universität Tübingen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts, Eberhard Karls Universität Tübingen filed Critical Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
Publication of PL3402821T3 publication Critical patent/PL3402821T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL17701290.3T 2016-01-14 2017-01-16 Przeciwciało wiążące psma i jego zastosowania PL3402821T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16151281.9A EP3192810A1 (en) 2016-01-14 2016-01-14 Psma binding antibody and uses thereof
PCT/EP2017/050834 WO2017121905A1 (en) 2016-01-14 2017-01-16 Psma binding antibody and uses thereof

Publications (1)

Publication Number Publication Date
PL3402821T3 true PL3402821T3 (pl) 2024-03-04

Family

ID=55349634

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17701290.3T PL3402821T3 (pl) 2016-01-14 2017-01-16 Przeciwciało wiążące psma i jego zastosowania

Country Status (16)

Country Link
US (3) US11612646B2 (pl)
EP (3) EP3192810A1 (pl)
JP (1) JP6893939B2 (pl)
CN (1) CN108699157B (pl)
AU (2) AU2017207947B9 (pl)
CA (2) CA3199697A1 (pl)
DK (1) DK3402821T5 (pl)
ES (1) ES2963561T3 (pl)
FI (1) FI3402821T3 (pl)
HU (1) HUE064205T2 (pl)
IL (1) IL260402B2 (pl)
PL (1) PL3402821T3 (pl)
PT (1) PT3402821T (pl)
RU (1) RU2762704C2 (pl)
WO (1) WO2017121905A1 (pl)
ZA (1) ZA201804601B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6441079B2 (ja) * 2011-12-19 2018-12-19 シンイミューン ゲーエムベーハー 二重特異性抗体分子
EP3192810A1 (en) 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof
CN112351820B (zh) 2018-06-21 2024-10-11 瑞泽恩制药公司 双特异性抗psma x抗cd28抗体及其用途
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL299748A (en) 2020-07-08 2023-03-01 Lava Therapeutics N V Antibodies that bind PSMA and T gamma delta receptors
WO2022060901A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
CN114349867B (zh) * 2020-10-14 2024-05-28 广东菲鹏制药股份有限公司 融合蛋白及其应用
EP4255574A1 (en) * 2020-12-01 2023-10-11 Aptevo Research and Development LLC Heterodimeric psma and cd3-binding bispecific antibodies
AU2021392655A1 (en) * 2020-12-01 2023-06-22 The Johns Hopkins University Methods and materials for treating t cell cancers
CN112480260B (zh) * 2020-12-09 2022-03-08 福州迈新生物技术开发有限公司 抗psma蛋白单克隆抗体、细胞系及其制备方法和应用
KR20230137393A (ko) * 2021-01-28 2023-10-04 얀센 바이오테크 인코포레이티드 Psma 결합 단백질 및 이의 용도
CN117580867A (zh) * 2021-01-28 2024-02-20 詹森生物科技公司 Psma结合蛋白及其用途
WO2022232376A1 (en) 2021-04-29 2022-11-03 Amgen Inc. Methods for reducing low molecular weight species of recombinantly-produced proteins
WO2022251253A1 (en) 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes
CA3253777A1 (en) 2022-03-21 2023-09-28 Amgen Inc. Polytherapeutic methods with T-lymphocyte-activating molecules for treating prostate cancer
TW202405015A (zh) * 2022-04-11 2024-02-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｐｓｍａ和ｃｄ２８的抗原結合分子及其醫藥用途
JP2026507228A (ja) 2023-03-03 2026-02-27 アーセナル バイオサイエンシズ インコーポレイテッド Ｐｓｍａ及びｃａ９を標的とするシステム
WO2025041836A1 (ja) * 2023-08-23 2025-02-27 Meiji Seika ファルマ株式会社 新規抗切断型変異ｃａｌｒ－ｃｄ３二重特性抗体及び医薬組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
US20100183615A1 (en) 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
SG10201808730VA (en) 2007-04-03 2018-11-29 Amgen Res Munich Gmbh Cross-species-specific binding domain
DK2352763T4 (da) * 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
BRPI0922839A2 (pt) * 2008-12-05 2019-09-03 Molecular Insight Pharmaceuticals, Inc. radiofarmacêuticos específicos de ca-ix para tratamento e imageamento de câncer.
JP6441079B2 (ja) 2011-12-19 2018-12-19 シンイミューン ゲーエムベーハー 二重特異性抗体分子
CN105531374A (zh) * 2013-07-12 2016-04-27 酵活有限公司 双特异性cd3和cd19抗原结合构建体
JP6693872B2 (ja) * 2013-07-25 2020-05-13 シトムクス セラピューティクス，インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
EP3119902A4 (en) * 2014-03-18 2017-11-29 Aptevo Research and Development LLC Cell line-based redirected t-cell cytotoxicity assay
LT3132247T (lt) 2014-04-16 2021-12-10 Juno Therapeutics Gmbh Ląstelių populiacijos padauginimo būdai, rinkiniai ir priemonės
EP2985294A1 (en) * 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
EP3192810A1 (en) 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof

Also Published As

Publication number Publication date
US20190022205A1 (en) 2019-01-24
RU2018128414A3 (pl) 2020-10-20
EP3693396A2 (en) 2020-08-12
IL260402B1 (en) 2023-08-01
WO2017121905A1 (en) 2017-07-20
ZA201804601B (en) 2019-04-24
CN108699157A (zh) 2018-10-23
IL260402A (pl) 2018-08-30
AU2023203041A1 (en) 2023-06-08
AU2017207947B2 (en) 2023-09-07
US12398208B2 (en) 2025-08-26
IL260402B2 (en) 2023-12-01
HUE064205T2 (hu) 2024-02-28
JP6893939B2 (ja) 2021-06-23
EP3693396A3 (en) 2020-10-14
EP3402821A1 (en) 2018-11-21
CN108699157B (zh) 2022-02-01
AU2017207947A1 (en) 2018-07-26
EP3402821B1 (en) 2023-08-23
CA3011098A1 (en) 2017-07-20
AU2017207947B9 (en) 2023-09-21
DK3402821T3 (da) 2023-11-06
JP2019505589A (ja) 2019-02-28
DK3402821T5 (da) 2024-09-23
US20250346669A1 (en) 2025-11-13
EP3192810A1 (en) 2017-07-19
PT3402821T (pt) 2023-09-26
BR112018014215A2 (pt) 2018-12-26
CA3199697A1 (en) 2017-07-20
FI3402821T3 (fi) 2023-10-26
US20230132249A1 (en) 2023-04-27
ES2963561T3 (es) 2024-03-27
NZ744221A (en) 2025-07-25
RU2762704C2 (ru) 2021-12-22
RU2018128414A (ru) 2020-02-14
US11612646B2 (en) 2023-03-28

Similar Documents

Publication Publication Date Title
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
IL262095A (en) Anti-pacap antibodies and uses thereof
IL264011A (en) Antibodies against tim3 and uses thereof
EP3481869A4 (en) ANTI-CD73 ANTIBODIES
IL257324A (en) Antibody against glypican-3 and application thereof
PL3383916T3 (pl) Przeciwciała anty-cd73 i ich zastosowania
DK3625259T3 (da) Anti-sirpalpha-antistoffer
DK3411404T3 (da) Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner
DK3350220T3 (da) Anti-pro/latente-myostatin-antistoffer og anvendelser deraf
HUE045307T2 (hu) EGFRVIII-ellenes antitestek és alkalmazásaik
DK3529269T3 (da) Antistof-konstruktioner
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
IL256099A (en) Antibody
DK3606961T3 (da) Garp-tgf-beta-antistoffer
IL271398A (en) Anti-l1-cam antibodies and uses thereof
EP3710486C0 (en) X-Factor Antibodies
IL262251A (en) New anti-sirpa antibodies and their therapeutic applications
DK3359563T3 (da) Antigenreceptorer og anvendelser deraf
EP3672987C0 (en) ANTI-APELIN ANTIBODIES AND THEIR USES
DK3110447T3 (da) Anti-EGFR-antistof og anvendelser heraf
PL3455261T3 (pl) Przeciwciała anty-ror2, fragmenty przeciwciał, ich immunokoniugaty oraz ich zastosowania
EP3529273A4 (en) ANTI-O1 ANTIBODIES AND USES THEREOF
IL257368A (en) Antibody
DK3245219T3 (da) Glypicanepitoper og anvendelser deraf